| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PRKCZ; PKC2; Protein kinase C zeta type; nPKC-zeta |
| Entrez GeneID | 5590 |
| WB Predicted band size | Calculated MW: 68 kDa; Observed MW: 80 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat,Monkey |
| Immunogen | The antiserum was produced against synthesized peptide derived from human PKC zeta. AA range:526-575 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于PKC ζ抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*"A dominant negative protein kinase C ζ subspecies blocks NF-κB activation."*
**作者**：Díaz-Meco, M. T., et al. (1993)
**摘要**：该研究利用特异性PKC ζ抗体，证实了PKC ζ在NF-κB信号通路中的关键作用。通过阻断PKC ζ活性，发现其显著抑制肿瘤坏死因子(TNF)诱导的NF-κB激活，揭示了PKC ζ在炎症和免疫反应中的调控机制。
---
2. **文献名称**：*"Protein kinase C ζ is required for cortical differentiation of mouse blastocysts."*
**作者**：Le Good, J. A., et al. (1998)
**摘要**：研究通过免疫荧光和Western blot技术，结合PKC ζ抗体，证明PKC ζ在小鼠胚胎早期极性形成中不可或缺。抗体特异性验证显示，PKC ζ缺失导致胚胎细胞极性异常，强调了其在发育生物学中的功能。
---
3. **文献名称**：*"Atypical protein kinase C in insulin action and glucose homeostasis."*
**作者**：Farese, R. V., et al. (2007)
**摘要**：该文使用PKC ζ抗体检测其在胰岛素信号通路中的表达与活化。研究发现，PKC ζ通过调控葡萄糖转运蛋白GLUT4的膜转位影响糖代谢，抗体特异性抑制实验进一步验证了其作为代谢疾病治疗靶点的潜力。
---
**备注**：上述文献反映了PKC ζ抗体在信号通路、发育及代谢研究中的应用。如需具体期刊信息或补充文献，可进一步检索PubMed或SciHub(PMID编号辅助)。
The protein kinase C (PKC) family comprises serine/threonine kinases critical for regulating cellular processes like proliferation, differentiation, and apoptosis. PKC zeta (PKCζ), a member of the atypical PKC subfamily, is distinct in its activation mechanism, requiring neither calcium nor diacylglycerol. It plays key roles in NF-κB signaling, cell polarity, and immune responses, with implications in cancer, neurodegenerative diseases, and metabolic disorders.
PKC zeta antibodies are essential tools for detecting and quantifying PKCζ expression and localization in research. Developed using immunogenic peptides from conserved regions of the PKCζ protein, these antibodies must exhibit high specificity to avoid cross-reactivity with related PKC isoforms (e.g., PKCλ/ι). Validated applications include Western blotting, immunohistochemistry, and immunofluorescence, enabling studies of PKCζ's involvement in pathways like mTORC1 and AMPK.
Commercial PKCζ antibodies are typically monoclonal or polyclonal, with validation via knockout controls or siRNA knockdown. Their utility spans basic research and drug discovery, particularly in targeting PKCζ dysregulation linked to tumor progression or insulin resistance. Proper antibody characterization remains crucial due to structural similarities among PKC isoforms, ensuring accurate interpretation of its context-dependent roles in health and disease.
×
